{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:01:12Z","timestamp":1791284472895,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Economic Development and Innovation Operative Programme Grant","award":["GINOP 2.3.2-15-2016-00048"],"award-info":[{"award-number":["GINOP 2.3.2-15-2016-00048"]}]},{"name":"Human Resources Development Operational Programme Grant","award":["EFOP-3.6.2-16-2017-00006"],"award-info":[{"award-number":["EFOP-3.6.2-16-2017-00006"]}]},{"name":"Human Resources Development Operational Programme Grant","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The quadrivalent human papillomavirus (HPV) vaccine has been assumed to give protection against genital warts (GW) as well as cervical cancer. Our main question was whether HPV vaccine has any effects on the prevention of GW reported in randomised controlled clinical trials (RCTs) and time-trend analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This meta-analysis was performed according to the PRISMA guidelines using the PICO format. We searched in three electronic databases (PubMed, Embase, Cochrane Trials), and assessed heterogeneity using the Q-test and I-squared statistics, meta-regression was also performed. Odds ratios (OR) and their confidence intervals (CI) were calculated. The sensitivity was tested by leave-one-out method. We evaluated the presence of publication bias using the funnel plot graph and the Copas selection model. The strength of evidence was assessed using the GRADE approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight RCTs (per-protocol populations) and eight time-trend ecological studies were included in this meta-analysis. A significant reduction (pooled OR\u2009=\u20090.03, 95% CI: 0.01\u20130.09; I-squared\u2009=\u200953.6%) of GW in young women was recorded in RCTs, and in time-trend analyses both in young women (pooled OR\u2009=\u20090.36, CI 95%\u2009=\u20090.26\u20130.51; I-squared\u2009=\u200998.2%), and in young men (pooled OR\u2009=\u20090.69, 95% CI\u2009=\u20090.61\u20130.78; I-squared\u2009=\u200992.7%). In subgroup analysis, a significant reduction of the number of GW events was observed especially in women under 21\u2009years (pooled OR\u2009=\u20090.33, 95% CI\u2009=\u20090.17\u20130.63). Leave-one-out analysis showed that similar results could be obtained after excluding one study, meta-regression did not show significant difference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Prophylactic, quadrivalent HPV vaccination can prevent GW in healthy women and men, therefore, it should be included in routine immunization programme.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12889-020-08753-y","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T23:05:33Z","timestamp":1590620733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-8920","authenticated-orcid":false,"given":"Anita","family":"Luk\u00e1cs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"M\u00e1t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Mik\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Tenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3 M\u00e1rk","family":"Czumbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaeng","family":"Wuttapon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Gy\u00f6ngyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Rumbus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"8753_CR1","doi-asserted-by":"crossref","unstructured":"Committee Opinion No. 704 summary: human papillomavirus vaccination. Obstet Gynecol 2017;129(6):1155\u201356.","DOI":"10.1097\/AOG.0000000000002111"},{"issue":"9","key":"8753_CR2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cmi.2015.05.001","volume":"21","author":"S Pils","year":"2015","unstructured":"Pils S, Joura EA. From the monovalent to the nine-valent HPV vaccine. Clin Microbiol Infect. 2015;21(9):827\u201333.","journal-title":"Clin Microbiol Infect"},{"key":"8753_CR3","unstructured":"World Health Organization: Weekly Epidemiological Record: Human papillomavirus vaccines: WHO position paper. 2017;19(92):241\u201368. http:\/\/appswhoint\/iris\/bitstream\/handle\/10665\/255353\/WER9219pdf;jsessionid=573ED31BAADB8A92056F43BD30296B37?sequence=1 Accessed 20 June 2018."},{"key":"8753_CR4","unstructured":"World Health Organization: Human papillomavirus (HPV) and cervical cancer. Key facts. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papillomavirus-(hpv)-and-cervical-cancer Accessed 20 June 2018."},{"key":"8753_CR5","unstructured":"World Health Organization: Data, statistics and graphics. http:\/\/www.who.int\/immunization\/monitoring_surveillance\/data\/en\/ Accessed 27 Jan 2020."},{"issue":"5","key":"8753_CR6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","volume":"15","author":"M Drolet","year":"2015","unstructured":"Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565\u201380.","journal-title":"Lancet Infect Dis"},{"key":"8753_CR7","first-page":"Cd009069","volume":"5","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:Cd009069.","journal-title":"Cochrane Database Syst Rev."},{"key":"8753_CR8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2017.12.017","volume":"122","author":"G Bogani","year":"2018","unstructured":"Bogani G, Leone Roberti Maggiore U, Signorelli M, Martinelli F, Ditto A, Sabatucci I, et al. The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. Crit Rev Oncol Hematol. 2018;122:92\u20137.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"8753_CR9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/OLQ.0000000000000948","volume":"46","author":"AE Yakely","year":"2019","unstructured":"Yakely AE, Avni-Singer L, Oliveira CR, Niccolai LM. Human papillomavirus vaccination and Anogenital warts: a systematic review of impact and effectiveness in the United States. Sex Transm Dis. 2019;46(4):213\u201320.","journal-title":"Sex Transm Dis"},{"issue":"10197","key":"8753_CR10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","volume":"394","author":"M Drolet","year":"2019","unstructured":"Drolet M, B\u00e9nard \u00c9, P\u00e9rez N, Brisson M. HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497\u2013509.","journal-title":"Lancet."},{"issue":"12","key":"8753_CR11","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.jogc.2018.05.024","volume":"40","author":"M Steben","year":"2018","unstructured":"Steben M, Tan Thompson M, Rodier C, Mallette N, Racovitan V, DeAngelis F, Melissa Stutz M, Rampakakis E. A review of the impact and effectiveness of the Quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J Obstet Gynaecol Can. 2018;40(12):1635\u201345.","journal-title":"J Obstet Gynaecol Can"},{"issue":"1","key":"8753_CR12","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","volume":"1","author":"M Brisson","year":"2016","unstructured":"Brisson M, B\u00e9nard \u00c9, Drolet M, Bogaards JA, Baussano I, V\u00e4nsk\u00e4 S, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8\u2013e17.","journal-title":"Lancet Public Health"},{"issue":"5","key":"8753_CR13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","volume":"364","author":"ARJ Giuliano","year":"2011","unstructured":"Giuliano ARJ, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401\u201311.","journal-title":"N Engl J Med"},{"issue":"1","key":"8753_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/sextrans-2017-053150","volume":"94","author":"L Westfechtel","year":"2018","unstructured":"Westfechtel L, Werner RN, Dressler C, Gaskins M, Nast A. Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis. Sex Transm Infect. 2018;94(1):21\u20139.","journal-title":"Sex Transm Infect"},{"issue":"7","key":"8753_CR15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"12","key":"8753_CR16","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.vaccine.2019.01.069","volume":"37","author":"H Mikamo","year":"2019","unstructured":"Mikamo H, Yamagishi Y, Murata S, Yokokawa R, Han SR, Wakana A, Sawata M, Tanaka Y. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study. Vaccine. 2019;37(12):1651\u20138.","journal-title":"Vaccine"},{"issue":"7","key":"8753_CR17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132404","volume":"10","author":"G Dominiak-Felden","year":"2015","unstructured":"Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of Quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PLoS One. 2015;10(7):e0132404.","journal-title":"PLoS One"},{"key":"8753_CR18","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http:\/\/handbook.cochrane.org."},{"key":"8753_CR19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"issue":"19","key":"8753_CR20","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928\u201343.","journal-title":"N Engl J Med"},{"key":"8753_CR21","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c5128","volume":"341","author":"J Dillner","year":"2010","unstructured":"Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.","journal-title":"BMJ."},{"issue":"10","key":"8753_CR22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1468-3083.2009.03266.x","volume":"23","author":"S Majewski","year":"2009","unstructured":"Majewski S, Bosch FX, Dillner J, Iversen OE, Kjaer SK, Munoz N, et al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol. 2009;23(10):1147\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"8753_CR23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","volume":"95","author":"LL Villa","year":"2006","unstructured":"Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459\u201366.","journal-title":"Br J Cancer"},{"issue":"5","key":"8753_CR24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","volume":"102","author":"N Munoz","year":"2010","unstructured":"Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM. Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325\u201339.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"8753_CR25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ijc.23260","volume":"122","author":"G Perez","year":"2008","unstructured":"Perez G, Lazcano-Ponce E, Hernandez-Avila M, Garcia PJ, Munoz N, Villa LL, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008;122(6):1311\u20138.","journal-title":"Int J Cancer"},{"issue":"4","key":"8753_CR26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/cas.12106","volume":"104","author":"H Yoshikawa","year":"2013","unstructured":"Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci. 2013;104(4):465\u201372.","journal-title":"Cancer Sci"},{"key":"8753_CR27","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","volume":"346","author":"H Ali","year":"2013","unstructured":"Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.","journal-title":"BMJ."},{"issue":"3","key":"8753_CR28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/sextrans-2014-051813","volume":"91","author":"EPF Chow","year":"2015","unstructured":"Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214\u20139.","journal-title":"Sex Transm Infect"},{"issue":"9","key":"8753_CR29","volume":"9","author":"C Harrison","year":"2014","unstructured":"Harrison C, Britt H, Garland S, Conway L, Stein A, Pirotta M, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS One. 2014;9(9):e105967.","journal-title":"PLoS One"},{"issue":"7","key":"8753_CR30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","volume":"85","author":"CK Fairley","year":"2009","unstructured":"Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85(7):499\u2013502.","journal-title":"Sex Transm Infect"},{"issue":"7","key":"8753_CR31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","volume":"87","author":"TR Read","year":"2011","unstructured":"Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transmit Infect. 2011;87(7):544\u20137.","journal-title":"Sex Transmit Infect"},{"key":"8753_CR32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/sextrans-2018-053751","volume":"95","author":"M Checchi","year":"2019","unstructured":"Checchi M, Mesher D, Mohammed H, Soldan K. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017. Sex Transm Infect. 2019;95:368\u201373.","journal-title":"Sex Transm Infect"},{"issue":"9","key":"8753_CR33","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/infdis\/jiy684","volume":"219","author":"LM Mann","year":"2019","unstructured":"Mann LM, Llata E, Flagg EW, Hong J, Asbel L, Carlos-Henderson J, Kerani RP, Kohn R, Pathela P, Schumacher C, Torrone EA. Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010\u20132016. J Infect Dis. 2019;219(9):1389\u201397.","journal-title":"J Infect Dis."},{"issue":"1","key":"8753_CR34","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1086\/425271","volume":"191","author":"GP Garnett","year":"2005","unstructured":"Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis. 2005;191(1):S97\u2013106.","journal-title":"J Infect Dis"},{"issue":"7","key":"8753_CR35","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/IGC.0b013e3181a3d100","volume":"19","author":"LR Medeiros","year":"2009","unstructured":"Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer. 2009;19(7):1166\u201376.","journal-title":"Int J Gynecol Cancer"},{"key":"8753_CR36","doi-asserted-by":"crossref","unstructured":"Patel C, Brotherton JML, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018;23(41):1700737.","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737"},{"issue":"1","key":"8753_CR37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21149\/7824","volume":"59","author":"RA Tejada","year":"2017","unstructured":"Tejada RA, Vargas KG, Benites-Zapata V, Mezones-Holguin E, Bolanos-Diaz R, Hernandez AV. Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis. Salud Publica Mex. 2017;59(1):84\u201394.","journal-title":"Salud Publica Mex"},{"key":"8753_CR38","doi-asserted-by":"crossref","first-page":"d7694","DOI":"10.1136\/bmj.d7694","volume":"343","author":"Z Kmietowicz","year":"2011","unstructured":"Kmietowicz Z. UK will use Gardasil in its HPV vaccination programme from next September. BMJ. 2011;343:d7694.","journal-title":"BMJ."},{"issue":"1452","key":"8753_CR39","first-page":"9","volume":"130","author":"J Oliphant","year":"2017","unstructured":"Oliphant J, Stewart J, Saxton P, Lo M, Perkins N, Ward D. Trends in genital warts diagnoses in New Zealand five years following the quadrivalent human papillomavirus vaccine introduction. N Z Med J. 2017;130(1452):9\u201316.","journal-title":"N Z Med J"},{"issue":"25","key":"8753_CR40","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.vaccine.2017.04.080","volume":"35","author":"E Navarro-Illana","year":"2017","unstructured":"Navarro-Illana E, Lopez-Lacort M, Navarro-Illana P, Vilata JJ, Diez-Domingo J. Effectiveness of HPV vaccines against genital warts in women from Valencia. Spain Vaccine. 2017;35(25):3342\u20136.","journal-title":"Spain Vaccine"},{"issue":"1","key":"8753_CR41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.23736\/S0026-4946.17.05147-7","volume":"70","author":"F Quattrone","year":"2018","unstructured":"Quattrone F, Canale A, Filippetti E, Tulipani A, Porretta A, Lopalco PL. Safety of HPV vaccines in the age of nonavalent vaccination. Minerva Pediatr. 2018;70(1):59\u201366.","journal-title":"Minerva Pediatr"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-08753-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T06:26:32Z","timestamp":1666679192000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-08753-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["8753"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-08753-y","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"17 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"691"}}